Meeting
2017 Gastrointestinal Cancers Symposium
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
Authors
Jordi Bruix
BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain
Jordi Bruix , Philippe Merle , Alessandro Granito , Yi-Hsiang Huang , Gyorgy Bodoky , Marc Pracht , Osamu Yokosuka , René Gerolami , Gianluca Masi , Paul J. Ross , Shukui Qin , Tianqiang Song , Jean-Pierre Bronowicki , Isabelle Ollivier-Hourmand , Masatoshi Kudo , Marie-Aude Le Berre , Gerold Meinhardt , Guohong Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT01774344
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 229)
DOI
10.1200/JCO.2017.35.4_suppl.229
Abstract #
229
Poster Bd #
A7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
First Author: Gregory Naylor
Poster
2017 Gastrointestinal Cancers Symposium
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
First Author: Richard S. Finn
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu